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ABSTRACT
Ranged among laminopathies, Hutchinson–Gilford progeria syndrome is a syndrome that involves premature aging, leading usually 
to death at the age between 10 to 14 years predominatly due to a myocardial infarction or a stroke. In the lecture I shall overview 
the importance of molecular cell biology investigations that led to the discovery of the basic mechanism standing behind this rare 
syndrome. The genetic basis in most cases is a mutation at the nucleotide position 1824 of the lamin A gene. At this position, cytosine 
is substituted for thymine so that a cryptic splice site within the precursor mRNA for lamin A is generated. This results in a production 
of abnormal lamin A, termed progerin, its presence in cells having a deleterious dominant effect. Depending on the cell type and 
tissue, progerin induces a pleiotropy of defects that vary in different tissues. The present endeavour how to challenge this terrible 
disease will be also mentioned. 
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result  from  a  nucleotide  position  1824CT  mutation 
(substitution mutation from cytosine to thymine) in the 
gene coding lamin A (LMNA) that creates an ectopic 
mRNA splicing site leading to an expression of truncated 
prelamin A. If compared to “normal” prelamin A protein, 
truncated prelamin A lacks 50 amino acids within its tail 
domain. Both normal and truncated prelamin A proteins 
are subjects to extensive post-translational modifications 
(PTMs). The PTMs play an important role in the HGPS 
story. 
Generally speaking, it should be noted here that the 
causes of many human diseases are due to an incorrect 
splicing of various precursor mRNAs.
Organization of the nuclear envelope
The nucleus of human cells (and of eukaryotic cells in 
general) is delimited by a nuclear envelope (NE) formed by 
two membranes, the inner nuclear membrane (INM) and 
the outer nuclear membrane (ONM). Importantly, the NE 
Introduction
I  work  in  the  field  of  molecular  cell  biology  and  the 
projects of our laboratory are distant from pharmacology 
and toxicology. Therefore, instead of showing you results 
from some work originating from our laboratory (see 
kindly “http://lge.lf1.cuni.cz“), I shall tell you a story of 
the Hutchison-Gilford progeria syndrome (HGPS) that 
explicitly documents the importance of molecular cell 
biology investigations in human medicine. In order to 
fulfill this aim simply, I explain here the results of only a 
few of the relevant experiments that are directly linked to 
the HGPS story. 
The HPGS is one type of laminopathies, alternatively 
called the nuclear envelope diseases. Most cases of HGPS 
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keeps separate most of the genome (= nuclear DNA) as 
well as other nuclear components (such as some enzymes) 
separated from cytosolic components. The nucleus is an 
important example of cellular compartmentalization that 
allows the cell to properly function. Biochemical reactions 
are facilitated by the high concentration of both substrates 
and enzymes within cell compartments.
The nuclear envelope is “punctured” by large nuclear 
pore complexes (NPCs) at sites where the ONM and INM 
join. The NPCs serve for a transport of (macro)molecules 
between the nucleus and the cytosol (cytoplasm). The 
nuclear envelope is, via the ONM, directly connected to 
the membranes of the endoplasmic reticulum. The INM 
is structurally supported by a nuclear lamina, the core 
of which consists of a network of intermediate filaments 
(IF) composed of lamin proteins belonging to the family 
of intermediate filament proteins. Many other proteins 
are associated with the nuclear lamina, such as hetero-
chromatin protein 1 (HP1), which provides a link between 
the lamina and chromatin, or the protein BAF (barrier 
to autointegration factor) which is a part of the protein 
complex linking the INM with the lamina.
Numerous integral membrane proteins are embedded 
in both ONM and INM and exhibit lateral movements 
within the membrane. Some proteins anchored within 
the ONM associate with cytoplasmic cytoskeleton (e.g. 
actin  and  intermediate  filaments).  Moreover,  some 
proteins  anchored  within  the  INM  can  interact  with 
proteins within the ONM. Many of those proteins in the 
NE physically interact, either directly or via a protein 
complex, with the nuclear lamina that underlies the INM, 
and are called lamin-associated polypeptides (LAPs; one 
such protein is BAF). 
A few words on splicing
The first steps of gene expression occur in the cell nucleus. 
Typically,  the  synthesis  and  processing  of  precursor 
mRNA (pre-mRNA) take place there. 
A gene is transcribed and this process gives rise to a 
primary transcript, a pre-mRNA. This precursor molecule 
is then processed. I mention here three major processing 
(“maturation”) events: 
i.  capping  –  chemical  modification  of  the  5´end 
of  the  pre-mRNA  and  generation  of  the  “cap” 
structure; 
ii.  polyadenylation  –  the  terminal  3´end  of  pre-
mRNA is cleaved and (tens of) adenines are added 
at the 3´end; 
iii.  splicing – a process during which non-coding 
sequences (introns) are cleaved away from pre-
mRNA and remaining coding sequences (exons) 
are joined (ligated) together. 
The mature mRNA is then transported into the cyto-
plasm and its sequence is translated on ribosomes into a 
polypeptide chain. 
Splicing is a complicated process that involves many 
splicing factors and a number of small nuclear ribonu-
cleoproteins (snRNPs) containing small nuclear RNAs 
(snRNAs). Standard snRNPs contain snRNA of type U1, 
U2, U4, U5 or U6 (the letter U was used due to the high 
content of uridine in this type of RNA). 
There  are  special  consensus  nucleotide  sequence 
signals within the pre-mRNA that are necessary for the 
binding of snRNPs and variety of splicing factors. Among 
them, there is a consensus sequence at the beginning of 
intron sequence that is necessary for the binding of U1 
snRNP. Within this sequence, a consensus triplet GGU is 
found that plays a prime role in the story of HGPS. 
This being said, it is also necessary to review the pro-
cess of alternative splicing. Depending mainly on the cell 
type and the tissue, the fate of a given pre-mRNA may 
vary as different exons can be used in the generation of 
mature mRNA. This is well documented in the example 
of the mouse α-tropomyosin gene. For instance, in striated 
muscle cells, exon 1 and 3 are found in mature mRNA, but 
not exon 2. In contrast, in smooth muscle cells, exon 1 and 
2 are found in mature mRNA, but not exon 3. Accordingly, 
different α-tropomyosin molecules are synthesized in 
striated or smooth muscle. An analogous situation occurs 
in human cells which contain about 25 000-30 000 genes, 
but through alternative splicing many more (usually simi-
lar) proteins are found in the human body. The alternative 
splicing of pre-mRNA for lamin A/C is important for the 
HGPS story. 
Lamins 
Human cells contain two lamin genes, the gene for lamin 
B and the gene for lamin A/C (LMNA). Lamins B are 
expressed in most cells in both embryos and adults, and its 
expression is essential for nuclear integrity, cell survival, 
and normal development. In contrast, lamins A/C are dif-
ferentially expressed, and their appearance in any cell type 
is normally correlated with differentiation. Lamins A and 
lamin C are just splice variants. The lamin A/C gene pre-
mRNA contains 12 exons, and lamin A and C mRNAs are 
generated via alternative splicing of the same pre-mRNA. 
For the HGPS story, only the lamin A is relevant since 
mature lamin C mRNA does not contain exons 11 and 12. 
The contrasting expression patterns of lamins B and 
A/C, together with the finding that B-type lamins are 
essential for cell survival, have given rise to the notion 
that B-type lamins are the fundamental building blocks 
of the nuclear lamina, while A-type lamins have more 
specialized functions.
Laminopathies
Mutations in genes coding for lamins and LAPs give rise 
to a pleiotrophy of human diseases called laminopathies, 
also called nuclear envelope diseases. The great puzzle 
is that various tissues are affected in patients, and the 91
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diseases exhibit clinical variations and a genetic hetero-
geneity. Not only LMNA, which has over 200 mapped 
mutations,  but  also  emerin  (EMD),  the  zinc  protease 
(metallopeptidase) ZMPSTE24 (Face1), lamin B receptor 
(LBR), SUN2 (integral transmembrane INM protein that 
associates with Nesprin within the lumen of the NE), 
Nesprin, Torsin A, MAN1 (one of the three membrane 
proteins originally identified by human autoantibodies 
from a patient suffering from a collagen vascular disease) 
and many other LAPs may bear mutations. 
Hundreds  of  proteins  are  associated  with  the  NE. 
Depending on the cell type and the tissue, the proteome of 
the NE (i.e. proteins associated with NE/nuclear lamina) 
differ. Therefore, the genetic heterogeneity apparently 
plays a role in various manifestations of laminopathies as 
multiple interacting proteins cause variants of the disease 
(depending on a given mutation, a disruption of tissue 
specific complexes associated with NE/nuclear lamina 
may lead to various disease manifestations). 
Speaking about the importance of molecular cell biology 
investigations for human medicine, here already is an important 
message: human diseases have origin in the changed function-
ing of cells that may manifest itself differently in various cell 
types and tissues. 
This being said, let us begin with the HGPS story and 
focus on a de novo acquired mutation in the nucleotide 
position 1824 of the LMNA gene sequence.
The HGPS story
After birth, children bearing such a de novo acquired 
mutation have no symptoms of the disease. The disease 
onset is situated between 12 and 24 months after birth, 
with a life expectancy of 10 to 15 years. HGPS exhibits 
many features such as accelerated aging, cardiovascular 
defects, atherosclerosis, sclerotic skin, joint contractures, 
bone abnormalities, alopecia and growth impairment. 
Various tissues are affected differently, but children with 
HGPS have about normal cognitive and other brain func-
tions so that the kids are aware of their “special” situation. 
The kids usually pass away due to a myocardial infarction 
or a stroke. Fortunately, this disease is very rare and only 
1 in 4 millions children are affected.
Molecular cell biology helped to decipher the molecu-
lar cause standing behind the disease. I document here 
results of an important experiment. Small fragments of 
the skin were taken from HGPS and healthy (control) 
children, and respective skin fibroblasts were cultured. 
The fibroblasts were stained with DAPI, a fluorescent 
dye staining DNA, and labeled for LMNA with specific 
antibodies to lamin A. There is a striking difference in 
the appearance of nuclei. Most of the normal fibroblasts 
exhibit a “smooth” appearance of nuclei. In contrast, most 
of the diseased nuclei exhibit irregular shapes with inward 
facing protrusions (wrinkles). Clearly, the nuclear lamina 
was involved. What was behind this?
The  LMNA  gene  from  children  with  HGPS  was 
sequenced and it was established that in one of the two 
LMNA genes (human cells are diploid, therefore two 
chromosomes bear the LMNA gene), there is a mutation 
in the 11th exon at the nucleotide position 1824. At this 
position, T was substituted for C. With such a mutation, 
one would expect that nothing happens, as both of the 
coding triplets GGC and GGT code for the amino acid 
glycine  (at  the  protein  level:  Gly608Gly).  However,  a 
GGT sequence in DNA becomes a GGU sequence in the 
transcribed pre-mRNA. This generates a new (cryptic) 
splicing site, as the GGU triplet is important for the bind-
ing of U1 snRNP.
Messenger RNA of lamin A was analyzed by electro-
phoresis in gels and lamins A and lamin C analyzed by 
Western blotting in which detection of lamins A/C was 
performed with an antibody reacting both with lamin A 
and lamin C. Messenger RNA from the HGPS child exhib-
ited two bands in the gels, one for normal lamin A, and an 
additional band that was shorter by 150 nucleotides. This 
was due to the aberrant splicing of pre-mRNA. At the 
protein level, bands for both lamin A and lamin C were 
seen, but an additional reactive band was also seen that 
was shorter by 50 amino acids with respect to lamin A 
(150 nucleotides in mRNA correspond to 50 amino acids 
in protein). It corresponded to the aberrant smaller lamin 
A protein, designated ∆-lamin A. This ∆-lamin A protein 
was later called progerin. 
How does the HGPS mutation cause the diseased cell 
phenotype? There are two explanations possible. Either 
the level of normal lamin A protein is insufficient to 
maintain the normal nuclear lamina function, causing a 
haplo-insufficiency effect, or the mutant protein disrupts 
normal lamina function, which would be considered a 
dominant negative effect. 
Cell  biology  again  helped  to  settle  this  problem. 
Diseased and normal fibroblasts were transfected with 
one of two plasmids. One carried the sequence coding for 
normal lamin A, the other for ∆-lamin A. These sequences 
were ligated to the sequence coding for green fluorescent 
protein (GFP). Bearing in mind that not all cells were 
successfully transfected and allowed for the expression 
of recombinant proteins lamin A-GFP or ∆-lamin A-GFP, 
the results of these experiments were clear cut. If progeric 
fibroblasts were transfected with lamin A-GFP plasmid, 
the abnormal nuclear phenotype was not rescued after 
transfection. This meant that additional “normal” lamin A 
proteins did not rescue the phenotype. Therefore, haplo-
insuficience is not valid. In contrast, if healthy cells were 
transfected with ∆-lamin A-GFP, the nuclei of transfected 
cells exhibited an abnormal shape. Thus, the dominant 
negative effect applies and the presence of progerin is the 
cause of the disease phenotype. 
An  experiment  using  fluorescence  recovery  after 
photobleaching (FRAP; a method in optical microscopy 
for determining the mobility of proteins within a cell - a 
rationale of this method is explained in the reference by 
Lippincott-Schartz & Patterson, 2003) brought another 
important  cell  biology  result.  In  this  experiment  all 92
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combinations of healthy or HGPS cells and transfections 
with  lamin  A-GFP  or  ∆-lamin  A-GFP  plasmids  were 
assayed. An important message followed from this experi-
ment - progerin was "cemented" in the nuclear lamina, 
and  the  cell  was  accumulating  this  aberrant  protein. 
Moreover, the exchange of normal lamin A molecules 
within the nuclear lamina was lowered. The mechanical 
properties of the NE were also changed, for example the 
nuclei of diseased cells were often ruptured during nuclear 
microinjection  experiments.  Thus,  it  seems  that  the 
nuclear envelope is much more “stiff” in cases of HGPS. 
In summary, HGPS is not due to haplo-insufficiency, 
as reintroduction of additional “wild type” lamin A is 
insufficient for rescue. In contrast, the progerin itself 
generates the abnormal cell phenotype, it accumulates in 
the lamina, and the dynamics of the nuclear membrane 
are decreased. 
Is it possible to rescue the phenotype of the diseased 
cells, and eventually help the children with HGPS? There 
is no way to repair the deleterious mutation throughout 
the whole human body. Remaining potential possibilities 
are at the level of the aberrant mRNA and/or progerin.
Reversal of the HGPS cellular 
phenotype at the mRNA level
It is indeed possible to eliminate the aberrant LMNA 
mRNA in HGPS cells cultured in vitro. For this purpose, 
short  complementary  antisense  morpholino  oligo-
nucleotides (morpholino oligonucleotides have a chemical 
structure that is resistant to nucleases) to aberrant pre-
mRNA were synthesized. The sequence of oligonucleotides 
encompassed the nucleotide 1824 mutation site. 
The oligonucleotides were introduced into diseased 
cells and bound at the mutation site of most abberant 
pre-mRNAs. The splicing machinery could not function 
because U1 snRNP could not bind to the cryptic splicing 
site. As a net result, basically just the normal splicing could 
occur in the cell. The result at the cell level was excellent: 
while HGPS cells exhibited 70% of aberrant nuclei, such 
cells after treatment with antisense oligonucleotides exhib-
ited only 10% of aberrant nuclei, i.e. about the same number 
as healthy (control) cells exhibiting 7% of aberrant nuclei. 
Via  inhibitory  oligonucleotides,  one  could  indeed 
experimentally rescue the cell phenotype in cells cultured 
in vitro. However, within the human body, no convenient 
way to administer such oligonucleotides to all cells is 
known. 
Is there a way, at the level of progerin, to improve the fate 
of children suffering from HGPS? Before replying, I have 
to tell you about the PTMs of prelamin A and progerin.
Posttranslational modifications 
of prelamin A and progerin
Messenger RNA for lamin A is translated, giving rise to 
the precursor protein “prelamin A,” which is subject to 
extensive PTMs. One of the modifications is addition of 
a farnesyl group to prelamin A. At the C-end of normal 
(as well as progeric) prelamin A, the polypeptide chain 
has a special sequence of 4 amino acids, cysteine-serine-
isoleucine-methionine (CSIM) sequence. This sequence, 
termed generally a „CAAX box“, is the target site of an 
enzyme – farnesyl transferase (FTase). The enzyme adds 
to the cysteine of the CSIM sequence a lipophilic farnesyl 
group. Cysteine farnelysation results in the association of 
prelamin A as well as progerin with the (lipophilic) INM. 
It should be noted that farnesylation of proteins is a com-
mon feature of numerous proteins containing CAAX box 
sequences (e.g., Ras protein is farnesylated).
In the cell, still other modifications of prelamin A take 
place. For example, the sequence SIM is cleaved away and 
is replaced by carboxymethylation of cysteine. However, 
the important modification for HGPS is that the terminal 
sequence in prelamin A is cleaved by the endoprotease 
Zmpste24. This protease cleaves off the end of the prela-
min A sequence, including the farnesylated cysteine, and 
gives rise to mature lamin A protein. Lamin A is thus no 
longer targeted to the INM. Importantly, this cleavage 
cannot take place in the progerin molecule as the endo-
protease needs the missing 50 amino acids to perform the 
cleavage job. As the results, progerin remains anchored to 
the INM and accumulates there. 
In summary, farnesylation of progerin has a deleteri-
ous effect on the diseased cell. 
And importantly, I documented here how molecular cell biol-
ogy helped to discover the basic mechanism behind the HGPS. 
Reversal of the HGPS cell phenotype 
and initial clinical trials with 
inhibitors of farnesyl transferase 
How  about  blocking  the  farnesylation  of  progerin? 
Inhibitors of the farnesyl transferase are known (e.g. the 
drugs Tipifarnib and Ionafarbid) and can be administered 
to patients similarly as standard drugs. At the cell level, 
the aberrant nuclear form seen in progeric cells can be 
rescued by FTase inhibitors. 
Using FTase inhibitors, very promising experimental 
results have been obtained with mice exhibiting a muta-
tion  in  the  LMNA  gene  and  manifesting  HGPS-like 
syndrome. I shall document how the histologic picture 
of the descending aorta of 9-12 month old progeric mice 
is improved. Daily administration of inhibitor prevented 
the loss of the vascular smooth muscle cells seen in non 
treated progeric animals.
Highly demanding clinical treatments have now begun 
at Harvard University (USA) with HGPS children from all 
over the world. It is to be emphasized that other cellular 
processes are affected by the FTase inhibitor treatments 
because, besides progerin, many other proteins need to 
be farnesylated in order to perform their physiological 
function. In other words, the administration of FTase 
inhibitors necessarily exhibits toxic effects. When the 93
also available online on intertox.sav.sk & versita.com/science/medicine/it
Interdisciplinary Toxicology. 2010; Vol. 3(3): 89–93
Copyright © 2010 Slovak Toxicology Society SETOX
toxic effects manifest themselves, the treatment of the 
children with HGPS is discontinued until manifestations 
of toxicity disappear, then the administration of the drug 
is resumed. Personally, I am anxious to hear positive 
reports concerning this terrible disease. 
Experimental  and  clinical  investigation  of  the 
Hutchinson–Gilford  progeric  syndrome  is  potentially 
important from another point of view. It has been shown 
that some accumulation of progerin takes place in normal 
human cells during aging (the cell is not a robot and accu-
mulating failures occur in the cells). Despite the fact that 
children with HGPS have about normal brain function 
while central nervous system degeneration accompanies 
normal human aging, progress in our knowledge of HGPS 
may bring some important clues about the mechanisms of 
normal aging as well.
And I hope that, with the HGPS story, I was able to docu-
ment the importance of molecular cell biology investigations in 
human medicine.
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